Lyell Immunopharma (NASDAQ:LYEL) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $6.00 price objective on the stock.

Lyell Immunopharma Price Performance

Shares of Lyell Immunopharma stock opened at $2.54 on Tuesday. The firm has a market cap of $647.55 million, a PE ratio of -2.73 and a beta of -0.54. Lyell Immunopharma has a twelve month low of $1.32 and a twelve month high of $3.97. The business has a 50-day moving average price of $2.34 and a 200 day moving average price of $2.08.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. On average, sell-side analysts expect that Lyell Immunopharma will post -0.84 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of large investors have recently added to or reduced their stakes in LYEL. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter worth about $31,000. RPO LLC purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $38,000. Public Employees Retirement System of Ohio boosted its stake in shares of Lyell Immunopharma by 109.7% in the third quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after acquiring an additional 14,229 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Lyell Immunopharma by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock worth $57,000 after purchasing an additional 22,701 shares in the last quarter. Finally, Simplicity Wealth LLC purchased a new stake in shares of Lyell Immunopharma during the first quarter worth approximately $58,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.